Abstract A cross talk between tyrosine kinase receptors and mitogen-activated protein kinases (MAPKs) is proposed as involved in endocrine resistance. We wanted to investigate intratumoral levels of vascular endothelial growth factor receptor 2 (VEGFR2) and p38 MAPK in relation to relapse-free (RFS) and breast cancer corrected survival (BCCS) after adjuvant endocrine treatment, mainly tamoxifen for 2 or 5 years. We also wanted to investigate these markers in relation to early and late recurrences. VEGFR2 (n = 381) and p38 (n = 174) were determined by enzyme-linked immuno-sorbent assays in tumor homogenates from primary BC diagnosed 1993-1996. Wide ranges of VEGFR2 and p38 proteins were found; median 0.72 pg/lg DNA (range 0.0-11.66), and 0.04 pg/lg DNA (range 0.0-6.79), respectively. Detectable levels of p38 were registered in 65% and classified positive. Higher VEGFR2 were correlated to higher VEGF (P = 0.005), p38 MAPK (P = 0.018), negative ER (P = 0.008), larger tumors (P = 0.001), histopathological grade III (P = 0.018), distant metastasis (P = 0.044), shorter RFS (P = 0.013), and shorter BCCS (P = 0.017). Expression of p38 was significantly correlated with negative PgR (P = 0.044) and with early relapses (P = 0.021), while no difference was seen during the later follow-up period (P = 0.73). Higher VEGFR2 had a significant negative impact on both early (P = 0.029) and later recurrences (P = 0.018), while VEGF only predicted later relapses (P = 0.037). Our preliminary results suggest higher intratumoral levels of VEGFR2 and p38 MAPK as candidate markers of intrinsic resistance for adjuvant endocrine therapy.
Introduction
Extracellular stimuli initiated by mitogens, cytokines, and growth factors result in aberrations of normal cellular processes as proliferation, differentiation, neo-angiogenesis, and invasion, characteristic for cancer growth [1] . This is in part mediated through membrane receptors, such as the receptors tyrosine kinases (RTKs) and downstream mitogen-activated protein kinases (MAPKs) [2] . Increased angiogenesis has been demonstrated to be a significant negative prognostic factor in several solid tumors including breast cancer. Vascular endothelial growth factor (VEGF) is a potent growth factor for endothelial cells that is produced by tumor cells and mediates its effects by binding to VEGF receptors 1-3 (VEGFR1-3) [3] . These receptors are preferably expressed on endothelial cells, although recent data have shown VEGFR2 expression also on the breast cancer cells suggesting existence of autocrine stimulation in breast cancer progression [4] . Upon ligand binding, VEGFR dimerize and become autophosphorylated resulting in activation of signal transduction cascades including the MAPKs [5] . This is followed by phosphorylation of several cytosolic substrates which translocate to the nucleus, where they activate transcriptional factors resulting in proliferation and migration of endothelial cells into the surrounding stroma. Three MAPK families have been extensively studied; the extracellular regulated kinase (ERK), c-jun amino terminal kinase (JNK), and the high osmolarity glycerol response kinase (p38) [6, 7] . Activation of ERK has been attributed to growth factor signaling, while JNK and p38 are activated in response to growth factors and by a large spectrum of stress related stimuli [8] . The aim with endocrine therapy is to disrupt estrogen stimulation of breast cancer cells which are mediated via estrogen binding to the estrogen receptor (ER). The expression of steroid receptors is correlated to the benefit of endocrine therapy, with a higher effect in ER positive patients while the role of PgR has been debated [9] . Resistance to endocrine therapy has in part been attributed to abnormalities in growth factor signaling. Preclinical models of tamoxifen resistance have shown that the steroid receptors not only are functional in response to steroid hormones but also for multiple signal transduction pathways by a ligand-independent phosphorylation of the ER. Several RTKs, i.e., the insulin-like growth factor receptor (IGFR), the epidermal growth factor receptor (EGFR), as well as their downstream cascades, have shown to be part of this process [10, 11] . Also patients expressing significant levels of ER and/or PgR can have breast cancers that do not respond to endocrine therapy; either at the beginning of treatment (de novo or intrinsic resistance) or after prolonged use (acquired resistance). Data from preclinical model systems investigating initially endocrine sensitive BC cells subjected to long-term anti-estrogen therapy has revealed that there are several stages of acquired resistance with an over-time shift in ER as well as growth factor expression [12] . Patients with acquired resistance might benefit from other types of endocrine intervention as estrogen withdrawal or therapy with the pure antiestrogen fulvestrant [13, 14] , contrary to patients likely to develop intrinsic resistance, for which endocrine therapy alone should be avoided. Our aim was to investigate intratumoral levels of VEGFR2 and downstream activated p38 MAPK (referred to as p38) in relation to previously determined intratumoral VEGF levels, routine breast cancer factors, localization of relapses, and survival in patients subjected to adjuvant endocrine treatment. We also wanted to determine if expression of these factors had an impact on early and late relapses.
Patients and methods

Patients
A total of 679 consecutive patients with primary operable invasive breast cancer diagnosed from January 1, 1993 to December 31, 1996 at two institutions in Stockholm, Sweden had remaining tumor homogenates after determination of steroid receptors in clinical routine. A total of 404 patients were subjected to endocrine therapy as only adjuvant systemic treatment have previously been included in a study investigating VEGF in relation to outcome [15] . Patients with remaining preserved tumor homogenates were included in this study. Patients were identified by use of the Breast Cancer registry data base at the Regional Oncologic Centre, Karolinska University Hospital, Stockholm, Sweden, and are in detail described in previous publications [15, 16] . Patients with locally advanced breast cancer, presence of distant metastasis at diagnosis, or those subjected to neoadjuvant therapy were not included.
Tumor tissue preparation
Representative tumor tissue was cut out and frozen in liquid nitrogen for later analysis of estrogen-and progesterone levels. Frozen tumor tissue was homogenized and suspended in cold standard receptor buffer (10 mmol/l Tris pH 7.4, 1.5 mmol/l EDTA, 10 mmol/l sodium molybdate, 1.0 mmol/l monothioglycerol). Supernatants were collected after refrigerated centrifugation at 20,0009g and stored at -70°C. The pellet fractions were analyzed for DNA content by the method of Burton, to evaluate cell concentrations in samples.
ER and PgR analyses
ER and PgR content were determined in tumor homogenates by an enzyme immunoassay (Abbott Laboratories, Diagnostic Division, Abbott Park, IL). Receptor concentrations were expressed as fmol of receptor per microgram of DNA. The cut-off value used to separate ER or PgR positive from negative was 0.05 fmol receptor/lg DNA. Steroid receptor levels were used in clinical routine and performed once or twice weekly pending on number of incoming patients samples. The Department of Cytology, Karolinska University Hospital, Stockholm, Sweden participated in the external quality assessment program arranged by the EORTC-Receptor and Biomarker Group at the Quality Assessment Laboratory, University Medical Centre Nijmegen, the Netherlands [17] . VEGFR2 analysis A VEGFR2 assay was performed by use of a commercial quantitative immunoassay kit for human VEGFR2 (Quantikine, human VEGFR2, R & D Systems, Minneapolis, MN, USA) according to the manufacturers' recommendations. Tumor homogenates from the primary breast tumor were used. Briefly, a murine monoclonal antibody specific for VEGFR2 had been pre-coated onto a 96-well microplate. After incubation and washing steps, a secondary polyclonal antibody specific for VEGFR2 was added and used as detection antibody. VEGFR2 levels in patients' samples were expressed as pg/lg DNA. Analyses of VEGFR2 were performed in a row by one person.
Activated p38 MAPK analysis
A phospho-p38 MAPK assay was performed by use of a commercial quantitative immunoassay kit for human activated p38 MAPK (Biosource, human phospho-p38 MAPK, Invitrogen, Camarillo, CA, USA) according to the manufacturers' recommendations. Tumor homogenates from the primary breast tumor were used. In summary, a monoclonal antibody specific for p38 MAPK regardless of phosphorylation state had been pre-coated onto a 96-well microplate. After incubation and washing steps, a detection antibody specific for p38 MAPK phosphorylated at heroine 180 and 182 was added. p38 MAPK protein levels in patients' samples were expressed as pg/lg DNA. Analyses of p38 were performed in a row by one person.
Statistical methods
Pearson chi-square test was used to investigate associations between intratumoral levels of VEGFR2 and p38 MAPK with VEGF as well as routine clinical breast cancer parameters (tumor size, nodal status, histopathological grade, and age). The median levels of VEGFR2 and VEGF in the tumor tissue of all patients (n = 381) was used as cut-off point in the statistical analyses, as we wanted to avoid statistical manipulations. Previous publications from our group, as well as other research groups, have analyzed VEGF as a dichotomized variable in relation to survival [18] [19] [20] [21] . Patients with detectable levels of p38 were considered positive while those without detectable levels were classified as negative. Kruskal-Wallis test was used to test the null hypothesis of equal VEGFR2 and p38 distributions in samples from the two institutions.
The median follow-up time was defined as the median follow-up for those patients still alive and free from distant recurrences at latest follow-up. Survival was estimated using the Kaplan-Meier method and comparison between study groups was performed with the log-rank test for determination of relapse-free survival (RFS) and breast cancer corrected survival (BCCS), the latter as the majority of deaths were unrelated to breast cancer. Survival analyses were performed in the total patient population and in the steroid receptor positive group. In order to study the impact of the biomarkers on early and later relapses, the cohort was divided in two strata; patients with early relapses (B2 years of follow-up) and patients with late relapses (after 2 years of follow-up). The reason for choosing 2 years as cut-point was that patients included in the study received endocrine therapy, mainly tamoxifen for 2 or 5 years. Thereby we were sure that all relapses within the first period occurred early on during adjuvant treatment. Within each group survival was compared between p38 negative versus positive, VEGFR2 negative versus positive and VEGF negative versus positive patients. In order to evaluate the simultaneous effect on different factors on survival, the Cox's proportional hazard model was used. Factors were tested and included in a forward stepwise procedure. For each variable, the patients were classified in two prognostic categories, and the putative best prognosis category was used as the reference. The survival time was measured from date of diagnosis to first documented relapse or death. In all the tests the significance level was set to 0.05, and all tests were two-sided. The study design is done according to the REMARK criteria for tumor marker studies [22] .
Results
Patients characteristics
Information regarding patients' characteristics was obtained from the Breast Cancer database at the Regional Oncologic Centre, Karolinska University Hospital, Stockholm, Sweden. The database reveals information on all patients with primary breast cancer within the StockholmGotland region. Parameters registered were: date of diagnosis, age, way of detection (mammogram screening or not), type of surgery, tumor size according to the pathologic report, number of removed axillary lymph nodes, number of axillary metastases, and levels of ER and PgR. The database also includes the adjuvant therapy recommended (radiotherapy, adjuvant systemic therapy), date and type of first relapse, date and cause of death. Patients' records were used to collect data on histopathological type and grade and to control that correct data on the adjuvant therapy actually given were registered. Detailed characteristics of the patients are earlier described [15, 16] . A total of 679 consecutive patients with diagnosis of primary operable breast cancer from 1993 to 1996 at two institutions in Stockholm were identified. Of these, 404 patients received endocrine therapy as only systemic adjuvant therapy, mainly tamoxifen for 2 or 5 years (Table 1) . VEGF levels in relation to routine BC biomarkers and stage are previously published [15] . Determination of VEGFR2 and p38 were performed in remaining tumor homogenates in 381 and 174 patients, respectively. The endocrine therapy given to the 381 patients with data on VEGFR2 were: tamoxifen 2 years (n = 241); tamoxifen 5 years (n = 111); GnRH analogue alone or combined with tamoxifen (n = 29). Data on clinical stage and routine breast cancer markers are shown in Table 2 . The median age of patients included was 63 years (range 29-92) and the median follow-up time for patients alive 11.2 years. With this follow-up time a total of 86 recurrences (28 locally, 47 distant, and 11 both local and distant) have been registered. The study design was approved by the research ethics board of the Karolinska Institute, Stockholm, Sweden.
Expression of VEGFR2 and p38 MAPK Wide variances in determined levels of VEGFR2 and p38 were found. We did not find any statistically significantly difference in samples from the two participating institutions; Mann-Whitney U tests VEGFR2 (P = 0.59) (Fig. 1a ) and p38 (P = 0.36) (Fig. 1b) . The median level of VEGFR2 was 0.72 pg/lg DNA (range 0.0-11.66). Higher intratumoral VEGFR2 levels were statistically significant correlated with high VEGF expression (P = 0.005), expression of p38 MAPK (P = 0.018), negative ER (P = 0.008), larger tumors (P = 0.001), grade III tumors (P = 0.018), premenopausal status (P = 0.005), and distant metastasis (P = 0.014). No correlation was seen between VEGFR2 and PgR status, tumor size, or age (not shown). Detectable levels of p38 were registered in 113 out of 174 patients (65%) with remaining cytosols for analysis. Expression of p38 was only statistically significant correlated with negative PgR (P = 0.044).
Survival-univariate analysis
Higher intratumoral levels of VEGFR2 were statistically significantly correlated with shorter RFS (HR = 1.9; 95% CI 1.1-3.3; P = 0.023) and BCCS (HR = 2.3; 95% CI 1.044-5.034, P = 0.039). Moreover, high VEGFR2 had a significant impact on survival in both time periods; early relapses, 0-2 years of follow-up (P = 0.029) and later relapses in the subsequent period, [2 years of follow-up (P = 0.018) (Fig. 2a, b) . High VEGFR2 was associated with an increased risk of relapse (HR 1.6; 95% CI 0.901-2.913; P = 0.107) and breast cancer corrected survival (HR 2.4; 95% CI 0.955-5.988; P = 0.051) also in the receptor positive group, however, not reaching statistically significance. Expression of p38 was not correlated with survival in the total patient population when studied during the whole follow-up time; RFS (P = 0.774) or BCCS (P = 0.960. However, expression of p38 was significantly correlated to early relapses (P = 0.021) while no difference was seen after 2 years (P = 0.730). The probability of RFS and BCCS at 5 years follow-up is shown in Table 3 . Contrary, high expression of VEGF was only significantly associated with an increased risk for relapses after 2 years (P = 0.037), while no difference was seen in the early follow-up period (P = 0.550) (Fig. 3a, b ). In the group of patients with a BC positive for both ER and PgR, p38 remained as a predictor of early relapses (P = 0.006).
Survival-univariate analysis according to earlier determined VEGF and prognostic factors
Other factors with statistically significant prognostic value in the total patient population were VEGF: RFS (P = 0.003), BCCS (P = 0.002); ER status: RFS (P = 0.002), BCCS (P = 0.006); PgR status: RFS (P = 0.008), BCCS (P = 0.011); tumor size: RFS (P \ 0.01), BCCS (P = 0.002); nodal status: RFS (P \ 0.01), BCCS (P \ 0.01);
histological grade: RFS (P = 0.001), BCCS (P = 0.007); and age (P = 0.001), BCCS (P = 0.011). The same analyses were performed with the steroid receptor negative patients excluded resulting in the corresponding figures; VEGF: RFS (P = 0.0177), BCCS (P = 0.0321); tumor size: RFS (P \ 0.01), BCCS (P = 0.009); nodal status: RFS (P \ 0.01), BCCS (P\ 0.01); histological grade: RFS (P = 0.120), BCCS (P = 0.337); and age (P = 0.001), BCCS (P = 0.012).
Survival-multivariate analysis
A Cox proportional hazard regression model was used to estimate hazard ratios (HR) for recurrences and deaths. Analysis was performed in the whole patient population. Due to few events during the early follow-up period, analyses were not done separately with patients split in the two follow-up periods. Factors tested were those statistically significantly correlated with survival in univariate analyses. Patient's age was also included. HR above 1.0 indicated a greater risk of recurrence or death than for the comparative group set as reference. VEGFR2 was found as an independent statistically significant factor for RFS (HR = 1.8; 95% CI 1.1-2.8, P = 0.0016) and BCCS (HR = 1.8, 95% CI 1.1-3.2, P = 0.030), respectively. Other factors remaining significantly correlated to RFS were tumor size (HR = 2.2, P \ 0.001), nodal status (HR = 2.9, P \ 0.001), ER (HR = 1.9, P = 0.016), and age (HR = 1.7, P = 0.036). The same factors were found as independent predictors of BCCS; tumor size (HR = 1.9, P \ 0.001), nodal status (HR = 4.6, P \ 0.001), ER (HR = 1.9, P = 0.049), and age (HR = 3.0, P = 0.001) ( Table 4 ). Duration of tamoxifen treatment for 2 years was correlated with an increased risk of relapse; (HR = 1.4, P = 0.306), as well as breast cancer corrected survival (HR = 2.0, P = 0.122), however, not reaching statistical significance. Multivariate analyses were also calculated with the steroid receptor negative patients excluded with minor changes in the results; tumor size (HR 2.1, P = 0.01), nodal status (HR 2.7, P = 0.002), and age (HR 3.4, P = 0.004) remained statistically significant associated with relapse-free survival, while VEGFR2 were not (HR 1.6, P = 0.106). For BCCS, nodal status (HR 11.6, P \ 0.01) and VEGFR2 (HR 4.2, P = 0.027) remained as independent predictors of breast cancer corrected survival, while tumor size and age did not. Histological grade did not remain as an independent predictor of RFS or BCCS.
Discussion
We investigated the possible effect on survival of VEGFR2 and downstream p38 MAPK in primary breast cancer patients subjected to adjuvant endocrine treatment. The results showed that patients with high intratumoral level of VEGFR2 were more prone to develop distant metastases, and had an impaired survival. A huge amount of publications have shown higher expression of the ligand, VEGF to be correlated with shorter survival times in several tumor types including breast cancer [23] . VEGFR2 is less studied and the data concerning the prognostic and predictive role contradictory. In accordance to our results, a previous study including a large number of premenopausal patients randomized to tamoxifen for 2 years or no adjuvant endocrine therapy, showed that high VEGFR2 expression were correlated with reduced survival [24] . On the contrary, the same group could not demonstrate that VEGFR2 according to intratumoral levels of VEGF (P = 0.037) in breast cancer subjected to adjuvant tamoxifen expression was correlated with survival after adjuvant tamoxifen in ER positive postmenopausal patients [25] . VEGFR2 expression was in both studies determined by immunohistochemistry on tumor micro-arrays excluding technical problems solely as explanation for the different results. The latter study on postmenopausal women included fewer patients which in part may contribute to the discrepant results. Variable proportions of patients with Luminal A and B subtypes in pre-and postmenopausal women may also influence the results. In a recent study investigating the correlation between several potential tumor biomarkers and effect of neo-adjuvant chemotherapy, VEGFR2 did not add predictive information for relapse-free survival [26] . Examples of pathways involved in intrinsic resistance have been enhanced the activity of EGFR or IGFR that result in an impaired estrogen induction of the PgR [10, 11, 27] . However, tyrosine kinase receptors have also shown a role in acquired resistance in preclinical studies [28] . How to define patients with intrinsic and acquired resistance is not clear. We hypothesized that candidate markers found at early progress after short-time treatment could aid in identification of patients with intrinsic resistance in whom endocrine treatment alone should be avoided up-front. With this aim, we investigated the possible impact of VEGF, VEGFR2, and p38 MAPK on early and later recurrences separately. The time limit was set to 2 years as all relapses before 2 years of follow-up occurred when patients still were on treatment.
Intratumoral levels of VEGFR2 had a significant impact on both early and later recurrences. p38 was significantly correlated with an inferior outcome among patients with early relapses also when analyses were restricted to patients with both tumors positive for both ER and PgR. Our findings suggest the VEGFR2-p38 pathway as involved in intrinsic resistance in accordance with previous results in breast cancer cell lines [4, 29] . Expression of p38 was not correlated with later relapses, tumor stage or other breast cancer factors beside negative PgR a marker claimed to be part of intrinsic resistance [10, 11] . Preclinical studies in ERa-expressing endometrial cancer cells have shown multiple functions of p38 of importance in tamoxifen resistance. This includes promotion of ER nuclear localization, enhancement of ER co-activator interaction, as well as, ability to increase the tamoxifen-induced estrogen agonistic activity [30] . So far, publications on p38 and other MAPKs in clinical breast cancer populations have been scare with contradictory results. One publication supporting our findings showed that development of tamoxifen resistance during the short-time period of neoadjuvant therapy was accomplished by loss of PgR, and an increase in HER2, as well as activated p38 and ERK in some patients [31] . On the contrary, two retrospective clinical studies have shown higher expression of ERK in smaller breast tumors with lower proliferation rate as well as lower incidence of nodal involvement, and a favorable outcome after adjuvant tamoxifen [32, 33] indicating activation of different intracellular pathways in endocrine resistance.
The major drawback of this study is the small patient population, above all regarding p38 analyses, resulting in few events and less power in statistical analyses, unable to fully elucidate the role of p38 in endocrine resistance. Technical aspects on p38 should also be discussed. There are four different isoforms out of which p38a and p38c have been mostly studied and found to be of pro-apoptotic and proliferative nature, respectively. Since they appear to regulate each other the dominating one will consequently influence which pathway becomes activated [34] . The ELISA we used in our study was not constructed to discriminate between different p38 isoforms as specific antibodies at that time not were available. Our hypothesis is that the dominating isoform we detected might be p38c that induces proliferative pathways, as well as reduce the activation of p38a and thereby also inhibiting its own degradation. Moreover, p38c can contrary to the p38a be activated without phosphorylation, whereby it might be more likely to be preserved also in clinical samples. Despite that our sample size regarding above all p38 MAPK is small and needs to be enlarged and that we lack a randomized patient population, the results may be considered as hypothesis generating. The role of growth factor receptors as well as MAPKs in endocrine resistance deserves to be further studied also after proper treatments periods, i.e., 5 years, in patients subjected to newer endocrine compounds as the aromatase inhibitors, as well as in the molecular sub-types Luminal A and B.
